Pharma News

 

Merck
Merck today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S. Food & Drug Administration (FDA) Pre-License inspection and a European Medicines Agency (EMA) Marketing Authorization Application inspection. [...]
Thu, Oct 19, 2017
Source Pharmanews
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human body to evade detection by the immune system. The team, led by Associate Professor Sarah [...]
Thu, Oct 19, 2017
Source Pharmanews
AstraZeneca
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated [...]
Wed, Oct 18, 2017
Source Pharmanews
Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer. Three scientists have received $1.3 million in critical [...]
Wed, Oct 18, 2017
Source Pharmanews

 

(by Worldpharmanews)

Contact us
Medial D&P Ltd.
Gewerbestrasse 18
4123 Allschwil
Switzerland
Phone: +41 61 487 96 22
Fax. +41 61 487 96 20
medial@medialpharma.com